In a post-hoc analysis, treatment with sublingual immunotherapy (SLIT)-tablets targeting grass, ragweed, tree, or house dust mite (HDM) allergens proved effective for the corresponding allergen in adults diagnosed with allergic rhinitis/conjunctivitis (AR/C), whether they were sensitized to a single allergen (monosensitized) or multiple allergens (polysensitized). The study investigated the effectiveness and safety of SLIT tablets in AR/C. Researchers incorporated data from people (aged eighteen years and older) diagnosed with AR/C who took part in placebo-controlled, double-blind, phase III field trials.

These trials comprised four grass, two ragweed, two HDM, and one tree trial. Efficiency was examined utilizing the total combined score (TCS). This score was the sum of daily AR/C symptom and medication scores, throughout the pollen season for tree and grass trials, and during the peak pollen season for the ragweed trials compared to placebo. Furthermore, HDM SLIT-tablet's effectiveness was determined utilizing the total combined rhinitis score (TCRS). This score included the sum of daily rhinitis symptom and medication scores, over the final eight weeks of treatment versus placebo.

Key findings:

• Grass SLIT-tablet: Showed a remarkable 20% improvement in TCS for both monosensitized and polysensitized subjects
• Ragweed SLIT-tablet: Demonstrated a 19% amelioration in TCS for monosensitized individuals, while polysensitized subjects experienced a profound 27% improvement
• Tree SLIT-tablet: Exhibited a substantial 54% improvement in TCS for monosensitized patients and a commendable 34% betterment for polysensitized individuals
• HDM SLIT-tablet: Indicated a notable 20% betterment in TCRS for monosensitized subjects and a respectable 17% improvement for polysensitized patients

There was no discernible difference in the overall safety profile between subjects who were sensitized to a single allergen (monosensitized) and those sensitized to multiple allergens (polysensitized). Importantly, targeting a single relevant allergen with SLIT tablets effectively induced clinical improvements specific to that allergen in both monosensitized and polysensitized patients. With single-allergen immunotherapy proving effective irrespective of polysensitization, patients can now benefit from more targeted and personalized treatment approaches.